79. Leadership in rare diseases, Srini Ramanathan, SVP, R&D Sciences, Horizon Therapeutics

Srini Ramanathan, Ph.D., Senior Vice President, Research and Development Sciences Srini Ramanathan, Ph.D., joined Horizon Therapeutics in 2018. He leads Horizon’s research and development sciences, with portfolio oversight of discovery, preclinical research and development functions; he also oversees scientific due diligence for business development evaluations. He has worked in the biotechnology industry over 20 years and has been involved in drug approvals across ophthalmology, oncology and virology. Before joining Horizon, Ramanathan served as senior project leader at AbbVie, overseeing the development of multiple immunology programs for rheumatology and gastrointestinal indications. Prior to AbbVie, he served as global head of clinical pharmacology at Gilead Sciences with responsibilities for portfolio programs across all therapeutic areas. Ramanathan earned his Master of Science in pharmaceutics from Duquesne University and his doctorate in pharmaceutics from Rutgers University.